Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ARTO: adding SBRT to abi+ADT in oligomet CRPC → OS NR vs 50mo, HR 0.55 (0.33-0.92, unplanned); metastasis-directed RT signal extends into castration-resistance.
Prostate and CNS both interrogate RT's role. ARTO pushes metastasis-directed SBRT past the hormone-sensitive setting into oligomet CRPC (OS HR 0.55, unplanned endpoint), while EORTC 22033's mature LGG data show RT and dose-dense TMZ monotherapy interchangeable as first-line. Combined-modality, now SOC, went untested there.
read the full digest →Studies · 90
- EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTUNo PFS or OS difference between RT (28×1.8Gy) and dose-dense TMZ as first-line monotherapy for high-risk WHO grade 2 LGG, across all molecular subtypes.
- ARTOUnplanned OS: NR vs 50mo, HR 0.55 (0.33-0.92), p=0.021 adding SBRT to abi+ADT in oligomet CRPC.
- BART2-yr locoregional FFS 87.1% vs 76.0% (HR 0.43, p=0.04) favoring adjuvant RT post-cystectomy; OS not significant.
- ENZARAD (ANZUP 1303)Primary MFS endpoint negative (HR 0.88, p=0.34); enzalutamide benefit concentrated in cN1 (HR 0.43) and planned-pelvic-RT (HR 0.47) subgroups.
- ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal CancerMargin-negative (R0) resection drives survival and local control; preop RT or systemic therapy downsizes tumor to improve R0 likelihood.
- PRIMARY2PSMA-PET avoided biopsy in 49% while csPCa detection (12% vs 16%, diff −3.7%, 95% CI −8.9 to 1.5) was non-inferior to systematic biopsy.
- INDIBLADE2yr bladder-intact EFS 78% (67-90), OS 96% (91-100) with induction ipi/nivo then chemoRT in cT2-4aN0-2 MIBC.
- DOREMY5-yr LRFS 97.4% with dose-reduced 36 Gy/18fx preop RT in myxoid liposarcoma, median f/u 66mo.
- REVELUTIONAdjusted total plaque volume +68.9mm³ with leuprolide vs relugolix at 12mo, GnRH agonist accelerating coronary atherosclerosis.
- KEYNOTE-689 vs NIVOPOSTOP3y DFS ~63% vs 53% adding adjuvant nivo to post-op chemoRT (NIVOPOSTOP); perioperative pembro hits EFS (KEYNOTE-689) in resectable LA-HNSCC.
- GEC-ESTRO APBI Patient Selection Guidelines (2026 Update)Updated selection expands low-risk APBI to age >40, ≤30mm, pN0/pN1mi, all histologies, DCIS at ≥2mm margins; BRCA/TNBC/age<40/EIC/extensive-LVI contraindicated.
- ORIOLESABR cut 6-mo progression to 19% vs 61% (P=.005) and improved mPFS (NR vs 5.8mo, HR 0.30) in oligomet HSPC.